Log in
AMS:AGN

AEGON Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume5.50 million shs
Average Volume9.27 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. In addition, it develops medical and cosmetic treatments; therapies for non-alcoholic steatohepatitis and other liver diseases; inhibitor for the treatment of psoriasis and other autoimmune disorders; atopic dermatitis drug candidate; peri-ocular rings for extended drug delivery and reducing elevated intraocular pressure in glaucoma patients; and treatments for neurodegenerative disorders, including Alzheimer's disease. Further, the company develops RST-001, a novel gene therapy for the treatment of retinitis pigmentosa; small molecule therapeutics for inflammatory and fibrotic diseases; topical medicines for fat reduction; and delivery system and botulinum toxin-based prescription products. It has collaboration, option, and license agreement with Lyndra, Inc.; and strategic alliance and option agreement with Editas Medicine, Inc. Allergan plc also has licensing agreements with Assembly Biosciences, Inc.; MedImmune; and Heptares Therapeutics, Ltd. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.
Read More
AEGON logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.50 out of 5 stars


Industry, Sector and Symbol

Industry Drugs - Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+31-70-3443210

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees16,900
Next Earnings DateN/A
OptionableOptionable
30 days | 90 days | 365 days | Advanced Chart

Receive AGN News and Ratings via Email

Sign-up to receive the latest news and ratings for AGN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











AEGON (AMS:AGN) Frequently Asked Questions

Who are some of AEGON's key competitors?

What other stocks do shareholders of AEGON own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AEGON investors own include Micron Technology (MU), NVIDIA (NVDA), Okta (OKTA), Shopify (SHOP), salesforce.com (CRM), Danaher (DHR), Walt Disney (DIS), Tesla (TSLA), Trade Desk (TTD) and Abbott Laboratories (ABT).

Who are AEGON's key executives?

AEGON's management team includes the following people:
  • Mr. Brenton L. Saunders, Chairman, Pres & CEO (Age 49)
  • Mr. Matthew M. Walsh, Exec. VP & CFO (Age 52)
  • Mr. A. Robert D. Bailey, Exec. VP, Chief Legal Officer & Corp. Sec. (Age 56)
  • Mr. William Meury, Exec. VP & Chief Commercial Officer (Age 51)
  • Dr. C. David Nicholson, Exec. VP and Chief R&D Officer (Age 64)

What is AEGON's stock symbol?

AEGON trades on the AMS under the ticker symbol "AGN."

What is AEGON's official website?

The official website for AEGON is www.aegon.nl.

How can I contact AEGON?

AEGON's mailing address is AEGONplein 50, 'S-GRAVENHAGE, 2591 TV, Netherlands. The company can be reached via phone at +31-70-3443210.

This page was last updated on 9/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.